Impact of COVID-۱۹ on ۷۵ Immunocompromised Patients: Does Immunosuppression Alter the Clinical Course?
- سال انتشار: 1400
- محل انتشار: فصلنامه عفونت، اپیدمیولوژی و پزشکی، دوره: 7، شماره: 2
- کد COI اختصاصی: JR_IEM-7-2_004
- زبان مقاله: انگلیسی
- تعداد مشاهده: 390
نویسندگان
Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Student Research Committee, School of Medicine, Shahid Beheshti University of medical sciences, Tehran, Iran
Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Taleghani and Imam Ali hospitals clinical research development center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Infectious diseases and tropical medicine research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Backgrounds: Currently, clinical details of immunosuppressed patients suffering from COVID-۱۹ are limited. Some studies have shown no more severe diseases among them, but others have highlighted that immunosuppressed patients may have high levels of viral load and impaired immune responses. Herein, this study aimed to specifically address the symptoms, prognosis, laboratory tests, clinical course, and the outcome of SARS-CoV-۲ infected immunocompromised patients at a tertiary referral center. Materials & Methods: Clinical and laboratory information of ۷۵ non-congenital immunosuppressed patients with COVID-۱۹ disease was obtained at a referral center for immunodeficiency diseases and infectious disorders in Tehran, Iran. Three groups of immunocompromised patients were evaluated, including patients with a history of organ transplantation, autoimmune patients receiving medical therapy, and cancer patients undergoing chemotherapy. Findings: Among ۷۵ immune-deficient patients with COVID-۱۹, there were ۳۲ patients with a kidney transplant, ۲۳ patients with malignancies, and ۱۹ patients with autoimmune disorders. One patient had both malignancy and multiple sclerosis. The mean length of hospitalization was ۱۰.۸۲ days. By the end of the study, ۲۴ (۳۲%) patients were dead, and ۵۱ (۶۸%) patients were discharged. Dyspnea was the most common (۶۴%) symptom. Low levels of O۲ saturation and lymphopenia at admission time significantly affected the mortality rate of patients. Conclusion: This study showed that mortality rate among immunocompromised patients was ۳۲%. It seems that COVID-۱۹ has a worse outcome and a more severe clinical course in immunocompromised patients regardless of age, gender, and underlying diseases.کلیدواژه ها
COVID-۱۹, Immun ocompromised patients, Cancer, Kidney transplantاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.